Cardarine (GW501516)

A 2023 pilot study showed complete resolution of NASH (non-alcoholic steatohepatitis) in 6-8 patients on the Cardarine/Retatrutide combination within 16 weeks. The speaker describes this as a 'cure' rather than management. Cardarine increases fat oxidation in the liver directly while Retatrutide prevents fat delivery to the liver and reduces hepatic fat synthesis capacity.

A 2017 study in Hepatology showed PPARδ activation reduced hepatic triglyceride content by 65% and improved hepatic insulin sensitivity. PPARδ also upregulates mitochondrial biogenesis in hepatocytes, reduces oxidative stress (primary driver of hepatic inflammation), and increases CPT1 gene expression for fatty acid beta-oxidation in the liver.

A 2019 study in Menopause showed that activating PPARδ in postmenopausal women improved insulin sensitivity by 35% and reduced visceral fat accumulation by 25%. This directly counteracts the metabolic catastrophe of menopause where estrogen drops 80-90%.

A 2018 study in Diabetes showed that increasing fatty acid oxidation (Cardarine's mechanism) reduced intramuscular lipid accumulation and improved insulin sensitivity by 40% independent of weight loss. This occurs by clearing the lipotoxic blockade (triglycerides and diacylglycerols) that impairs insulin receptor signaling.

A 2008 study showed PPARδ activation increased time to exhaustion in endurance exercise by 68%. This enhanced exercise capacity allows for greater caloric deficits through training, compounding the metabolic benefits of increased basal metabolic rate.

A 2010 study in Cell showed PPARδ activation increased whole-body energy expenditure by 20% independent of activity level. The speaker describes this as sustained upregulation of metabolic machinery, not a temporary boost, meaning users burn significantly more calories at rest.

A 2021 study in Nature Communications showed PPARδ activation specifically increased selective autophagy in adipose tissue while sparing myofibrillar protein. This mechanism explains how Cardarine directs energy deficits toward fat stores without catabolizing muscle tissue.

A 2006 study from PNAS showed PPARδ agonist activation increases type 1 (slow-twitch oxidative) muscle fibers, which are designed to burn fat and build mitochondrial density. The speaker claims this does not destroy capacity for growth or strength potential, but rather optimizes fat burning at the cellular level.

A 2009 study in Cell Metabolism demonstrated that PPARδ activation produced a 20% increase in oxygen utilization and preferentially burned lipids over glucose. Cardarine upregulates CPT1 (carnitine palmitoyltransferase), the gatekeeper protein that shuttles fatty acids into mitochondria for oxidation.

A 2008 study in the Journal of Biological Chemistry showed that PPARδ activation (Cardarine's target) increased mitochondrial density by over 40% within weeks. This mitochondrial biogenesis means cells create new mitochondria, effectively adding more 'power plants' for energy production.

By increasing mitochondrial density in muscle cells and hepatocytes, Cardarine improves oxidative capacity, reducing lipotoxicity. The speaker claims intramuscular and intrahepatic lipid accumulation drops by 50%, allowing insulin signaling to start working again. This addresses the root cause of type 2 diabetes rather than symptom management.

The speaker emphasizes that these compounds require proper diet and lifestyle to be effective. They are not shortcuts that work while eating poorly and being sedentary. Proper nutrition and activity are prerequisites for the metabolic benefits described.

The speaker briefly addresses the cancer concern with Cardarine, dismissing it by stating 'no, it does not cause cancer' and declining to elaborate further, noting he has addressed this topic many times before. No evidence or citations were provided for this safety claim.

The speaker describes the combination as 'metabolic rescue' for menopausal women. Cardarine's PPARδ activation increases estrogen receptor signaling in adipose and muscle tissue (not replacing estrogen, but making remaining estrogen more effective) and counteracts metabolic rate decline. Retatrutide's GLP-1 improves insulin sensitivity, stabilizes blood sugar, improves mood via serotonin/dopamine, and reduces hot flashes by acting on TRPV1 channels.

The speaker describes a two-pronged approach to insulin resistance reversal: Cardarine removes the lipotoxic blockade preventing insulin from working (clears the molecular traffic jam), then Retatrutide optimizes insulin secretion timing, pancreatic function, and hepatic insulin sensitivity. Together they transition patients from hyperinsulinemic to euinsulinemic states.

PPARδ activation via Cardarine upregulates adiponectin, an insulin-sensitizing hormone, and improves mitochondrial function. Better mitochondrial function means less oxidative stress and reactive oxygen species (ROS), which are direct inhibitors of insulin signaling. This provides an additional mechanism for insulin sensitivity improvement beyond lipotoxicity clearance.

The speaker argues that the Retatrutide/Cardarine combination prevents the metabolic plateaus that commonly occur during weight loss. Cardarine increases baseline energy expenditure and exercise capacity while Retatrutide prevents metabolic downregulation and preserves muscle. The speaker claims people on this combination lose 50+ pounds instead of hitting a wall at 20 pounds.

The speaker advocates combining Retatrutide with Cardarine (a PPARδ agonist) for synergistic fat loss. Retatrutide creates a caloric deficit through appetite suppression and increased energy expenditure, while Cardarine directs that deficit exclusively toward fat oxidation, sparing muscle. The speaker claims 40% body weight/fat reduction in 12-16 weeks versus 20-25% from either compound alone. No specific dosages were provided.